hek cells Search Results


93
ATCC human embryonic kidney hek cells
Human Embryonic Kidney Hek Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/tet-on+spiking+HEK+cells%3B+Embryonic+Kidney%3B+Human/pmc05349797-95-0-5
Average 93 stars, based on 1 article reviews
human embryonic kidney hek cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
TaKaRa cytomegalovirus cmv promoter
Cytomegalovirus Cmv Promoter, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK+293+Tet-On+3G+Cell+Line/pm33597243-310-13-16
Average 95 stars, based on 1 article reviews
cytomegalovirus cmv promoter - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
ATCC human embryonic kidney cells
Human Embryonic Kidney Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/Human+embryonic+kidney+cells+293SF-3F6/arxiv__2501__11553-233-2-7
Average 96 stars, based on 1 article reviews
human embryonic kidney cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech 293t cells
Figure 2. In vitro knockdown of human RHO-T17M expression. (A) Schematic view of construction of <t>293T</t> stably expressing human RHO protein and transfection of pX601-EFS-SaCas9-U6-sgRNA (SgRNA) plasmid. (B) T7E1 assay indicated that SaCas9/17-Sg1 and SaCas9/17-Sg2 were appeared to cut the mutant sequence specifically, the full-length amplicon was 760 bp, the two truncated amplicons were 510 bp and 250 bp, respectively. (C) The cutting efficacy of two sgRNAs with SaCas9 determined by TA and Sanger sequencing in 293T cells. (D) Rhodopsin expression reduction was determined by WB in RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, comparing to the RHOwt cells with 17-Sg1 and -Sg2 plasmid. (E) Densitometric analysis of immunoblots performed on RHOwt and RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, respectively. The experiment was performed in triplicate and presented as mean ± SEM, the significance was calculated using two-tailed paired t-test, ns = not significant, *p<0.05.
293t Cells, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK+293T+cells+Antibody/10__7554_slash_elife__84065-321-5-34
Average 96 stars, based on 1 article reviews
293t cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Proteintech hek293 cell conditioned medium
( A ) Domain structure of GDE2, GDE3 and GDE6 (left panel), and the transmembrane scheme of GDE3 (right panel). GDPD denotes catalytic glycerophosphodiesterase domain. Asterisk in GDPD domain depicts catalytic His residue in both GDE2 and GDE3. ( B ) Immunoblot analysis of uPAR release into the medium. <t>HEK-uPAR</t> cells transfected with empty vector (control), GDE2 or GDE3. PI-PLC served as positive control. ( C ) Mutant GDE3(H229A) fails to release uPAR. ( D ) Partial loss of uPAR from the plasma membrane by GDE3, as measured by flow cytometry. ( E ) TIRF microscopy reveals loss of uPAR from the basolateral plasma membrane. Box plot shows uPAR-GFP intensity at the ventral membrane (n = 3, mean ±SEM ****p<0001). ( F ) Homology modeling of the GDE2 and GDE3 catalytic domains showing surface charge distributions (blue, positive; red, negative; green line, putative GPI-binding groove; yellow line, proposed substrate-binding surface). The active site is indicated by glycerol-3-phosphate located at the template structure.
Hek293 Cell Conditioned Medium, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK+293+cells+Antibody/pmc05576486-136-13-20
Average 95 stars, based on 1 article reviews
hek293 cell conditioned medium - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
InvivoGen hek293 il 11 reporter cells
Combination of apo-hIGFBP4 with electropositive AAC2 nanofibers enhances glucose uptake and attenuates the proinflammatory effects of MGO. ( a ) Schematic representation of hIGFBP4 structure highlighting domains susceptible to interaction with charged, hydrophobic, and oxidant molecules. ( b ) AAC structure: a dilysine backbone modified with a hydrophobic coumarin side group, enabling self-assembly into positively charged nanofibers. ( c ) Schematic of methylglyoxal (MGO) production under hyperglycemic stress, showing its role as a precursor of electronegative AGEs and driver of diabetic inflammation. ( d ) FD-glucose uptake in human subcutaneous SVF preadipocytes isolated from obese patients ( n = 6) with and without diabetes. Confluent cells were glucose- and serum-deprived (starved) for 40 min and treated with vehicle (Veh, PBS) or designated concentrations of insulin (Ins), leptin (Lep), and hIGFBP4. Statistical analysis was performed using unpaired t-test. * P = 0.05–0.01; ** P = 0.01–0.001; *** P < 0.001. ( e ) Dose-dependent FD-glucose uptake in 3T3-L1 preadipocytes ( n = 4) starved for 50 min and treated for 90 min with hIGFBP4 alone or with AAC2 (0.1 µM). ( f <t>)</t> <t>IL-11</t> reporter activity in <t>HEK293</t> cells ( n = 4) after 24 h stimulation with recombinant human IL-11 (1 ng/mL), MGO (10 µM), or their combination. Data is expressed as a percentage relative to unstimulated control. ( g ) HEK293 cells ( n = 4) were stimulated for 24 h with IL-11 and MGO (as in panel f) in the presence or absence of AAC2 (1 µM), hIGFBP4 (50 ng/mL), or their combination
Hek293 Il 11 Reporter Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+IL-11+Cells/pmc12853802-264-0-4
Average 99 stars, based on 1 article reviews
hek293 il 11 reporter cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
InvivoGen hek blue il
a Schematic overview of the VHH selection strategy against <t>human</t> <t>IL-2</t> receptor subunits CD25 (IL-2Rα), CD122 (IL-2Rβ), and CD132 (IL-2Rγ). b – d Anti-CD25 ( b ), anti-CD122 ( c ), and anti-CD132 ( d ) VHH clones plotted by CDR3 sequence family versus binding capacity (dissociation rate k off ) to their recombinant targets. Colored dots indicate clones selected for further study. The dissociation rate constant ( k off ) was obtained by SPR off-rate screening, where periplasmic extracts containing soluble VHHs were injected over CM5 chips with immobilized IL-2R subunits, and k off was derived by fitting the dissociation phase of the sensorgrams after the association step (buffer wash only). The principle and analysis were the same for all IL-2R subunits (IL-2Rα, IL-2Rβ, IL-2Rγ); differences were limited to assay setup details such as the specific chip, immobilized ligand, pH for coupling, and regeneration conditions optimized for each subunit. e Domain architecture of VHH-hFc fusion constructs used for biochemical and cellular assays.
Hek Blue Il, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+IL-2+Cells/pmc13482293-323-23-28
Average 97 stars, based on 1 article reviews
hek blue il - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
InvivoGen hek blue mtlr7
Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue <t>mTLR7</t> and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.
Hek Blue Mtlr7, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+mTLR7+cells/pmc06397047-63-18-23
Average 99 stars, based on 1 article reviews
hek blue mtlr7 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen human embryonic kidney hek
Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue <t>mTLR7</t> and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.
Human Embryonic Kidney Hek, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+mTLR5+cells/pm37725584-151-16-24
Average 99 stars, based on 1 article reviews
human embryonic kidney hek - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen hek blue il 12 reporter cells
Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue <t>mTLR7</t> and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.
Hek Blue Il 12 Reporter Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+IL-12+Cells/us12071633-2069-0-4
Average 99 stars, based on 1 article reviews
hek blue il 12 reporter cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen hek blue null2 cells
Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue <t>mTLR7</t> and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.
Hek Blue Null2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+Null2+cells/pmc12258416-95-0-22
Average 99 stars, based on 1 article reviews
hek blue null2 cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen hek blue il 1r1 reporter cell line
Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue <t>mTLR7</t> and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.
Hek Blue Il 1r1 Reporter Cell Line, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek+cells/HEK-Blue+IL-1R+Cells/pmc13016199-106-10-14
Average 99 stars, based on 1 article reviews
hek blue il 1r1 reporter cell line - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


Figure 2. In vitro knockdown of human RHO-T17M expression. (A) Schematic view of construction of 293T stably expressing human RHO protein and transfection of pX601-EFS-SaCas9-U6-sgRNA (SgRNA) plasmid. (B) T7E1 assay indicated that SaCas9/17-Sg1 and SaCas9/17-Sg2 were appeared to cut the mutant sequence specifically, the full-length amplicon was 760 bp, the two truncated amplicons were 510 bp and 250 bp, respectively. (C) The cutting efficacy of two sgRNAs with SaCas9 determined by TA and Sanger sequencing in 293T cells. (D) Rhodopsin expression reduction was determined by WB in RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, comparing to the RHOwt cells with 17-Sg1 and -Sg2 plasmid. (E) Densitometric analysis of immunoblots performed on RHOwt and RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, respectively. The experiment was performed in triplicate and presented as mean ± SEM, the significance was calculated using two-tailed paired t-test, ns = not significant, *p<0.05.

Journal: eLife

Article Title: Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa

doi: 10.7554/elife.84065

Figure Lengend Snippet: Figure 2. In vitro knockdown of human RHO-T17M expression. (A) Schematic view of construction of 293T stably expressing human RHO protein and transfection of pX601-EFS-SaCas9-U6-sgRNA (SgRNA) plasmid. (B) T7E1 assay indicated that SaCas9/17-Sg1 and SaCas9/17-Sg2 were appeared to cut the mutant sequence specifically, the full-length amplicon was 760 bp, the two truncated amplicons were 510 bp and 250 bp, respectively. (C) The cutting efficacy of two sgRNAs with SaCas9 determined by TA and Sanger sequencing in 293T cells. (D) Rhodopsin expression reduction was determined by WB in RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, comparing to the RHOwt cells with 17-Sg1 and -Sg2 plasmid. (E) Densitometric analysis of immunoblots performed on RHOwt and RHO17 cells transfected with 17-Sg1 and -Sg2 plasmid, respectively. The experiment was performed in triplicate and presented as mean ± SEM, the significance was calculated using two-tailed paired t-test, ns = not significant, *p<0.05.

Article Snippet: For the production of lentivirus, 293T cells were transfected with a combination of three plasmids, FUGW- RHO- cDNA or Lenti_SaCRISPR_GFP, Pax2, and vesicular stomatitis virus G protein (VSV- G) plasmid using polyetherimide (PEI) (B600070, ProteinTech Group, Chicago, IL, USA) according to the manufacturer’s protocol.

Techniques: In Vitro, Knockdown, Expressing, Stable Transfection, Transfection, Plasmid Preparation, Mutagenesis, Sequencing, Amplification, Western Blot, Two Tailed Test

Figure 6. Expression of the mutant human RHO allele after gene editing with SaCas9/17-Sg2 in vitro. (A) Schematic view of the different human RHO gene variants created by gene editing. (Top) Map of the pEGFPN1 vector used to overexpress these variants. (Bottom) The description of variants at DNA and protein level. (B) Colocalization of GFP and rhodopsin (4D2, red) in 293T cells transfected with pEGFPN1 vector carrying RHO-WT, RHO-T17M, and four edited RHO-T17M variants, 1 week after transfection. Scale bar = 10 μm. (C) Colocalization of GFP and rhodopsin (4D2, red) in 293T cells transfected with pEGFPN1 vector carrying RHO-5m and four edited RHO-5m variants, 1 week after transfection. Scale bar = 10 μm. (D–F) The number of GFP+ cells and percentage of GFP+ cells expressing rhodopsin per random sight. Nuclei were stained blue by DAPI. Scale bar = 200 μm.

Journal: eLife

Article Title: Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa

doi: 10.7554/elife.84065

Figure Lengend Snippet: Figure 6. Expression of the mutant human RHO allele after gene editing with SaCas9/17-Sg2 in vitro. (A) Schematic view of the different human RHO gene variants created by gene editing. (Top) Map of the pEGFPN1 vector used to overexpress these variants. (Bottom) The description of variants at DNA and protein level. (B) Colocalization of GFP and rhodopsin (4D2, red) in 293T cells transfected with pEGFPN1 vector carrying RHO-WT, RHO-T17M, and four edited RHO-T17M variants, 1 week after transfection. Scale bar = 10 μm. (C) Colocalization of GFP and rhodopsin (4D2, red) in 293T cells transfected with pEGFPN1 vector carrying RHO-5m and four edited RHO-5m variants, 1 week after transfection. Scale bar = 10 μm. (D–F) The number of GFP+ cells and percentage of GFP+ cells expressing rhodopsin per random sight. Nuclei were stained blue by DAPI. Scale bar = 200 μm.

Article Snippet: For the production of lentivirus, 293T cells were transfected with a combination of three plasmids, FUGW- RHO- cDNA or Lenti_SaCRISPR_GFP, Pax2, and vesicular stomatitis virus G protein (VSV- G) plasmid using polyetherimide (PEI) (B600070, ProteinTech Group, Chicago, IL, USA) according to the manufacturer’s protocol.

Techniques: Expressing, Mutagenesis, In Vitro, Plasmid Preparation, Transfection, Staining

Figure 10. Examination of SaCas9/17-Sg2 off-target effects in human gDNA using WGS. Identification of SNVs (A) and indels (C) in 293T cells transfected with 17-Sg2 plasmid at the WGS level. The type of SNVs (B) and indels (D) in 293T cells transfected with 17-Sg2 plasmid and untreated cells at the WGS level.

Journal: eLife

Article Title: Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa

doi: 10.7554/elife.84065

Figure Lengend Snippet: Figure 10. Examination of SaCas9/17-Sg2 off-target effects in human gDNA using WGS. Identification of SNVs (A) and indels (C) in 293T cells transfected with 17-Sg2 plasmid at the WGS level. The type of SNVs (B) and indels (D) in 293T cells transfected with 17-Sg2 plasmid and untreated cells at the WGS level.

Article Snippet: For the production of lentivirus, 293T cells were transfected with a combination of three plasmids, FUGW- RHO- cDNA or Lenti_SaCRISPR_GFP, Pax2, and vesicular stomatitis virus G protein (VSV- G) plasmid using polyetherimide (PEI) (B600070, ProteinTech Group, Chicago, IL, USA) according to the manufacturer’s protocol.

Techniques: Transfection, Plasmid Preparation

( A ) Domain structure of GDE2, GDE3 and GDE6 (left panel), and the transmembrane scheme of GDE3 (right panel). GDPD denotes catalytic glycerophosphodiesterase domain. Asterisk in GDPD domain depicts catalytic His residue in both GDE2 and GDE3. ( B ) Immunoblot analysis of uPAR release into the medium. HEK-uPAR cells transfected with empty vector (control), GDE2 or GDE3. PI-PLC served as positive control. ( C ) Mutant GDE3(H229A) fails to release uPAR. ( D ) Partial loss of uPAR from the plasma membrane by GDE3, as measured by flow cytometry. ( E ) TIRF microscopy reveals loss of uPAR from the basolateral plasma membrane. Box plot shows uPAR-GFP intensity at the ventral membrane (n = 3, mean ±SEM ****p<0001). ( F ) Homology modeling of the GDE2 and GDE3 catalytic domains showing surface charge distributions (blue, positive; red, negative; green line, putative GPI-binding groove; yellow line, proposed substrate-binding surface). The active site is indicated by glycerol-3-phosphate located at the template structure.

Journal: eLife

Article Title: Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells

doi: 10.7554/eLife.23649

Figure Lengend Snippet: ( A ) Domain structure of GDE2, GDE3 and GDE6 (left panel), and the transmembrane scheme of GDE3 (right panel). GDPD denotes catalytic glycerophosphodiesterase domain. Asterisk in GDPD domain depicts catalytic His residue in both GDE2 and GDE3. ( B ) Immunoblot analysis of uPAR release into the medium. HEK-uPAR cells transfected with empty vector (control), GDE2 or GDE3. PI-PLC served as positive control. ( C ) Mutant GDE3(H229A) fails to release uPAR. ( D ) Partial loss of uPAR from the plasma membrane by GDE3, as measured by flow cytometry. ( E ) TIRF microscopy reveals loss of uPAR from the basolateral plasma membrane. Box plot shows uPAR-GFP intensity at the ventral membrane (n = 3, mean ±SEM ****p<0001). ( F ) Homology modeling of the GDE2 and GDE3 catalytic domains showing surface charge distributions (blue, positive; red, negative; green line, putative GPI-binding groove; yellow line, proposed substrate-binding surface). The active site is indicated by glycerol-3-phosphate located at the template structure.

Article Snippet: To determine the inositol phosphate content of cleaved uPAR, suPAR was immuno-precipitated from HEK293 cell conditioned medium using anti-GFP beads (ChromoTek).

Techniques: Residue, Western Blot, Transfection, Plasmid Preparation, Control, Positive Control, Mutagenesis, Clinical Proteomics, Membrane, Flow Cytometry, Microscopy, Binding Assay

( A ) Confocal images of HEK293 cells expressing human GDE2-HA, GDE3-HA or GDE6-HA, as indicated; bar, 10 μm. ( B ) GDE3 localizes to distinct microdomains (yellow square, open arrows) and filopodia-like extensions (orange square, solid arrow), as visualized by confocal and super-resolution microscopy. Bars, 10 μm and 1 μm respectively. ( C ) Immunoblot analysis showing that GDE3 reduces the membrane-anchored uPAR pool and competes with PI-PLC. The medium and lysates of HEK-uPAR cells expressing GDE3 or empty vector (EV) were analyzed without or with PI-PLC treatment (45 min.) of the cells, as indicated (left and right panels, respectively). Right lanes refer to wild-type (WT) HEK293 cells. ( D ) Expression and localization of GDE3 and mutant GDE3(H229A), as measured by immunoblotting and confocal microscopy, respectively, at 24 hr after transfection. Actin was used as a loading control. ( E ) uPAR-TM containing the transmembrane domain of EGFR is not released by GDE3, as shown by immunoblotting using anti-uPAR antibody, while uPAR-TM is properly expressed at the plasma membrane (bar, 10 μm).

Journal: eLife

Article Title: Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells

doi: 10.7554/eLife.23649

Figure Lengend Snippet: ( A ) Confocal images of HEK293 cells expressing human GDE2-HA, GDE3-HA or GDE6-HA, as indicated; bar, 10 μm. ( B ) GDE3 localizes to distinct microdomains (yellow square, open arrows) and filopodia-like extensions (orange square, solid arrow), as visualized by confocal and super-resolution microscopy. Bars, 10 μm and 1 μm respectively. ( C ) Immunoblot analysis showing that GDE3 reduces the membrane-anchored uPAR pool and competes with PI-PLC. The medium and lysates of HEK-uPAR cells expressing GDE3 or empty vector (EV) were analyzed without or with PI-PLC treatment (45 min.) of the cells, as indicated (left and right panels, respectively). Right lanes refer to wild-type (WT) HEK293 cells. ( D ) Expression and localization of GDE3 and mutant GDE3(H229A), as measured by immunoblotting and confocal microscopy, respectively, at 24 hr after transfection. Actin was used as a loading control. ( E ) uPAR-TM containing the transmembrane domain of EGFR is not released by GDE3, as shown by immunoblotting using anti-uPAR antibody, while uPAR-TM is properly expressed at the plasma membrane (bar, 10 μm).

Article Snippet: To determine the inositol phosphate content of cleaved uPAR, suPAR was immuno-precipitated from HEK293 cell conditioned medium using anti-GFP beads (ChromoTek).

Techniques: Expressing, Super-Resolution Microscopy, Western Blot, Membrane, Plasmid Preparation, Mutagenesis, Confocal Microscopy, Transfection, Control, Clinical Proteomics

( A ) (Left) Scheme showing uPAR cleavage in cis or trans. (Right) GDE3-expressing HEK-uPAR cells were mixed with a GDE3-deficient cell population, as indicated. Immunoblot analysis of uPAR in medium and cell lysates indicates that GDE3 acts in cis; mock refers to empty vector-transfected cells. ( B ) GDE3 expression leads to increased GPI-free suPAR. Conditioned medium from HEK-uPAR cells expressing GDE2 or GDE3 was subjected to Triton X-114 phase separation. suPAR in the aqueous ( A ) and detergent ( D ) fractions was analyzed by immunoblotting. ( C ) GPI-anchor with phospholipase cleavage sites indicated; HONO, nitrous acid. ( D ) Representative LC-MS ion chromatograms (m/z 259.02–259.03); inositol 1-phosphate peaks in red. HONO-treated suPAR contains inositol 1-phosphate (n = 3, mean ±SEM; *p<0.05).

Journal: eLife

Article Title: Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells

doi: 10.7554/eLife.23649

Figure Lengend Snippet: ( A ) (Left) Scheme showing uPAR cleavage in cis or trans. (Right) GDE3-expressing HEK-uPAR cells were mixed with a GDE3-deficient cell population, as indicated. Immunoblot analysis of uPAR in medium and cell lysates indicates that GDE3 acts in cis; mock refers to empty vector-transfected cells. ( B ) GDE3 expression leads to increased GPI-free suPAR. Conditioned medium from HEK-uPAR cells expressing GDE2 or GDE3 was subjected to Triton X-114 phase separation. suPAR in the aqueous ( A ) and detergent ( D ) fractions was analyzed by immunoblotting. ( C ) GPI-anchor with phospholipase cleavage sites indicated; HONO, nitrous acid. ( D ) Representative LC-MS ion chromatograms (m/z 259.02–259.03); inositol 1-phosphate peaks in red. HONO-treated suPAR contains inositol 1-phosphate (n = 3, mean ±SEM; *p<0.05).

Article Snippet: To determine the inositol phosphate content of cleaved uPAR, suPAR was immuno-precipitated from HEK293 cell conditioned medium using anti-GFP beads (ChromoTek).

Techniques: Expressing, Western Blot, Plasmid Preparation, Transfection, Liquid Chromatography with Mass Spectroscopy

( A ) Endogenous uPAR expression in MDA-MB-231 versus HEK293 cells, as determined by immunoblot. ( B ) Endogenous GDPD2 expression, as determined by qPCR analysis. ( C ) (left) Cell-surface expression of GDE3-mCherry of MDA-MB-231 cells expressing GDE3, as detected by flow cytometry. (Right) Cell-surface expression of uPAR in control (grey) and GDE3-expressing MDA-MB-231 cells (red), as detected by flow cytometry. ( D ) Confocal (top) and dual-color super-resolution microscopy images (bottom) of MDA-MB-231 cells expressing GDE3-GFP or catalytically dead GDE3(H229A)-GFP. Endogenous uPAR was immunostained in red. Merged images show colocalization of uPAR with GDE3(H229A) but not with wild-type GDE3 and uPAR. Scale bars, 10 μm (confocal) and 1 μm (super-resolution). Co-localization analysis (Mander's coefficient) on peripheral uPAR patches in confocal images was done using ImageJ software (n = 30 cells, three independent experiments). ( E ) Endogenous uPAR staining in control, GDE3-overexpressing and GDE3 knockout MDA-MB-231 cells plated on vitronectin. Two distinct GDE3 knockout clones (KO1 and KO2) were examined, as indicated. Scale bar,10 μm. ( F ) Quantification of basolateral uPAR-containing membrane domains referring to the cells in panel ( E ) (n = 3, mean ±SEM, ****p<0.0001). GDE3 suppresses the vitronectin- and uPAR-dependent phenotype of MDA-MB-231 breast cancer cells.

Journal: eLife

Article Title: Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells

doi: 10.7554/eLife.23649

Figure Lengend Snippet: ( A ) Endogenous uPAR expression in MDA-MB-231 versus HEK293 cells, as determined by immunoblot. ( B ) Endogenous GDPD2 expression, as determined by qPCR analysis. ( C ) (left) Cell-surface expression of GDE3-mCherry of MDA-MB-231 cells expressing GDE3, as detected by flow cytometry. (Right) Cell-surface expression of uPAR in control (grey) and GDE3-expressing MDA-MB-231 cells (red), as detected by flow cytometry. ( D ) Confocal (top) and dual-color super-resolution microscopy images (bottom) of MDA-MB-231 cells expressing GDE3-GFP or catalytically dead GDE3(H229A)-GFP. Endogenous uPAR was immunostained in red. Merged images show colocalization of uPAR with GDE3(H229A) but not with wild-type GDE3 and uPAR. Scale bars, 10 μm (confocal) and 1 μm (super-resolution). Co-localization analysis (Mander's coefficient) on peripheral uPAR patches in confocal images was done using ImageJ software (n = 30 cells, three independent experiments). ( E ) Endogenous uPAR staining in control, GDE3-overexpressing and GDE3 knockout MDA-MB-231 cells plated on vitronectin. Two distinct GDE3 knockout clones (KO1 and KO2) were examined, as indicated. Scale bar,10 μm. ( F ) Quantification of basolateral uPAR-containing membrane domains referring to the cells in panel ( E ) (n = 3, mean ±SEM, ****p<0.0001). GDE3 suppresses the vitronectin- and uPAR-dependent phenotype of MDA-MB-231 breast cancer cells.

Article Snippet: To determine the inositol phosphate content of cleaved uPAR, suPAR was immuno-precipitated from HEK293 cell conditioned medium using anti-GFP beads (ChromoTek).

Techniques: Expressing, Western Blot, Flow Cytometry, Control, Super-Resolution Microscopy, Software, Staining, Knock-Out, Clone Assay, Membrane

Combination of apo-hIGFBP4 with electropositive AAC2 nanofibers enhances glucose uptake and attenuates the proinflammatory effects of MGO. ( a ) Schematic representation of hIGFBP4 structure highlighting domains susceptible to interaction with charged, hydrophobic, and oxidant molecules. ( b ) AAC structure: a dilysine backbone modified with a hydrophobic coumarin side group, enabling self-assembly into positively charged nanofibers. ( c ) Schematic of methylglyoxal (MGO) production under hyperglycemic stress, showing its role as a precursor of electronegative AGEs and driver of diabetic inflammation. ( d ) FD-glucose uptake in human subcutaneous SVF preadipocytes isolated from obese patients ( n = 6) with and without diabetes. Confluent cells were glucose- and serum-deprived (starved) for 40 min and treated with vehicle (Veh, PBS) or designated concentrations of insulin (Ins), leptin (Lep), and hIGFBP4. Statistical analysis was performed using unpaired t-test. * P = 0.05–0.01; ** P = 0.01–0.001; *** P < 0.001. ( e ) Dose-dependent FD-glucose uptake in 3T3-L1 preadipocytes ( n = 4) starved for 50 min and treated for 90 min with hIGFBP4 alone or with AAC2 (0.1 µM). ( f ) IL-11 reporter activity in HEK293 cells ( n = 4) after 24 h stimulation with recombinant human IL-11 (1 ng/mL), MGO (10 µM), or their combination. Data is expressed as a percentage relative to unstimulated control. ( g ) HEK293 cells ( n = 4) were stimulated for 24 h with IL-11 and MGO (as in panel f) in the presence or absence of AAC2 (1 µM), hIGFBP4 (50 ng/mL), or their combination

Journal: Journal of Nanobiotechnology

Article Title: Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c

doi: 10.1186/s12951-025-03943-5

Figure Lengend Snippet: Combination of apo-hIGFBP4 with electropositive AAC2 nanofibers enhances glucose uptake and attenuates the proinflammatory effects of MGO. ( a ) Schematic representation of hIGFBP4 structure highlighting domains susceptible to interaction with charged, hydrophobic, and oxidant molecules. ( b ) AAC structure: a dilysine backbone modified with a hydrophobic coumarin side group, enabling self-assembly into positively charged nanofibers. ( c ) Schematic of methylglyoxal (MGO) production under hyperglycemic stress, showing its role as a precursor of electronegative AGEs and driver of diabetic inflammation. ( d ) FD-glucose uptake in human subcutaneous SVF preadipocytes isolated from obese patients ( n = 6) with and without diabetes. Confluent cells were glucose- and serum-deprived (starved) for 40 min and treated with vehicle (Veh, PBS) or designated concentrations of insulin (Ins), leptin (Lep), and hIGFBP4. Statistical analysis was performed using unpaired t-test. * P = 0.05–0.01; ** P = 0.01–0.001; *** P < 0.001. ( e ) Dose-dependent FD-glucose uptake in 3T3-L1 preadipocytes ( n = 4) starved for 50 min and treated for 90 min with hIGFBP4 alone or with AAC2 (0.1 µM). ( f ) IL-11 reporter activity in HEK293 cells ( n = 4) after 24 h stimulation with recombinant human IL-11 (1 ng/mL), MGO (10 µM), or their combination. Data is expressed as a percentage relative to unstimulated control. ( g ) HEK293 cells ( n = 4) were stimulated for 24 h with IL-11 and MGO (as in panel f) in the presence or absence of AAC2 (1 µM), hIGFBP4 (50 ng/mL), or their combination

Article Snippet: HEK293 IL-11 reporter cells (Invivogen, hkb-hil11rv2) were cultured in T-150 flasks using complete growth medium consisting of high-glucose DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, A5268-01), 1% penicillin-streptomycin, and 5 mM L-glutamine.

Techniques: Modification, Isolation, Activity Assay, Recombinant, Control

Expression of Cluster II genes in LSECs and Cluster I genes in other hepatic cell populations supports the scavenging input hypothesis underlying AAC2 and AAC2–hIGFBP4 regulation of capillarized and fenestrated LSEC phenotypes. ( a–g ) Correlation and mechanistic modeling support the scavenging input hypothesis underlying AAC2 and AAC2–hIGFBP4 regulation of LSEC phenotypes. ( a–b ) Cluster II genes expressed in LSECs significantly correlate with Cluster I genes expressed in other hepatic cell populations ( n = 12, R² > 0.33, P < 0.05; Pearson correlation). Specifically, Oit3 correlates positively with Klf9 ( a ), while Klf9 shows an inverse correlation with genes expressed in the hepatocyte-associated Cluster I ( b ). ( c ) Eng expression correlates with receptors of the TGFβ pathway and with Tgfb1 . ( d ) Fcgr2b expression is positively correlated with Adgrf5 . ( e ) Eng correlates with Smad family transcription factors. ( f ) Cdh5 expression is positively associated with Tgfb1 . ( g ) The proposed scavenging input hypothesis suggests that TGFβ production is stimulated by AGE uptake via stabilin 2 ( Stab2 ), which activates the canonical ALK5 pathway underlying the capillarized LSEC phenotype and induces transcription of Eng and other Cluster II genes. Translation of Eng mRNA to protein endoglin defines the transition to ALK1 signaling, which, in conjunction with Cluster II proteins, promotes the fenestrated LSEC phenotype. Endoglin mediates endocytosis that terminates the ALK1 state. This physiological cycle is sustained by renewed scavenger activity, leptin receptor ( Lepr ), and VEGFR2/VE-cadherin signaling, which reinforce TGFβ production adapted for amount of waste in circulation. Binding of positively charged AGEs with AAC2 may reduce scavenger receptor input and suppress the fenestrated LSEC state, whereas the AAC2–hIGFBP4 complex promotes the transition toward a fenestrated phenotype. Inflammatory conditions disrupt this physiological TGFβ cycle in LSEC through cytokines (e.g., IL-11), accumulation of toxic waste, or TGFβ derived from damaged or immune cells that drive a pathological process toward fibrosis

Journal: Journal of Nanobiotechnology

Article Title: Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c

doi: 10.1186/s12951-025-03943-5

Figure Lengend Snippet: Expression of Cluster II genes in LSECs and Cluster I genes in other hepatic cell populations supports the scavenging input hypothesis underlying AAC2 and AAC2–hIGFBP4 regulation of capillarized and fenestrated LSEC phenotypes. ( a–g ) Correlation and mechanistic modeling support the scavenging input hypothesis underlying AAC2 and AAC2–hIGFBP4 regulation of LSEC phenotypes. ( a–b ) Cluster II genes expressed in LSECs significantly correlate with Cluster I genes expressed in other hepatic cell populations ( n = 12, R² > 0.33, P < 0.05; Pearson correlation). Specifically, Oit3 correlates positively with Klf9 ( a ), while Klf9 shows an inverse correlation with genes expressed in the hepatocyte-associated Cluster I ( b ). ( c ) Eng expression correlates with receptors of the TGFβ pathway and with Tgfb1 . ( d ) Fcgr2b expression is positively correlated with Adgrf5 . ( e ) Eng correlates with Smad family transcription factors. ( f ) Cdh5 expression is positively associated with Tgfb1 . ( g ) The proposed scavenging input hypothesis suggests that TGFβ production is stimulated by AGE uptake via stabilin 2 ( Stab2 ), which activates the canonical ALK5 pathway underlying the capillarized LSEC phenotype and induces transcription of Eng and other Cluster II genes. Translation of Eng mRNA to protein endoglin defines the transition to ALK1 signaling, which, in conjunction with Cluster II proteins, promotes the fenestrated LSEC phenotype. Endoglin mediates endocytosis that terminates the ALK1 state. This physiological cycle is sustained by renewed scavenger activity, leptin receptor ( Lepr ), and VEGFR2/VE-cadherin signaling, which reinforce TGFβ production adapted for amount of waste in circulation. Binding of positively charged AGEs with AAC2 may reduce scavenger receptor input and suppress the fenestrated LSEC state, whereas the AAC2–hIGFBP4 complex promotes the transition toward a fenestrated phenotype. Inflammatory conditions disrupt this physiological TGFβ cycle in LSEC through cytokines (e.g., IL-11), accumulation of toxic waste, or TGFβ derived from damaged or immune cells that drive a pathological process toward fibrosis

Article Snippet: HEK293 IL-11 reporter cells (Invivogen, hkb-hil11rv2) were cultured in T-150 flasks using complete growth medium consisting of high-glucose DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, A5268-01), 1% penicillin-streptomycin, and 5 mM L-glutamine.

Techniques: Expressing, Activity Assay, Binding Assay, Derivative Assay

a Schematic overview of the VHH selection strategy against human IL-2 receptor subunits CD25 (IL-2Rα), CD122 (IL-2Rβ), and CD132 (IL-2Rγ). b – d Anti-CD25 ( b ), anti-CD122 ( c ), and anti-CD132 ( d ) VHH clones plotted by CDR3 sequence family versus binding capacity (dissociation rate k off ) to their recombinant targets. Colored dots indicate clones selected for further study. The dissociation rate constant ( k off ) was obtained by SPR off-rate screening, where periplasmic extracts containing soluble VHHs were injected over CM5 chips with immobilized IL-2R subunits, and k off was derived by fitting the dissociation phase of the sensorgrams after the association step (buffer wash only). The principle and analysis were the same for all IL-2R subunits (IL-2Rα, IL-2Rβ, IL-2Rγ); differences were limited to assay setup details such as the specific chip, immobilized ligand, pH for coupling, and regeneration conditions optimized for each subunit. e Domain architecture of VHH-hFc fusion constructs used for biochemical and cellular assays.

Journal: Nature Communications

Article Title: Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting

doi: 10.1038/s41467-026-75024-6

Figure Lengend Snippet: a Schematic overview of the VHH selection strategy against human IL-2 receptor subunits CD25 (IL-2Rα), CD122 (IL-2Rβ), and CD132 (IL-2Rγ). b – d Anti-CD25 ( b ), anti-CD122 ( c ), and anti-CD132 ( d ) VHH clones plotted by CDR3 sequence family versus binding capacity (dissociation rate k off ) to their recombinant targets. Colored dots indicate clones selected for further study. The dissociation rate constant ( k off ) was obtained by SPR off-rate screening, where periplasmic extracts containing soluble VHHs were injected over CM5 chips with immobilized IL-2R subunits, and k off was derived by fitting the dissociation phase of the sensorgrams after the association step (buffer wash only). The principle and analysis were the same for all IL-2R subunits (IL-2Rα, IL-2Rβ, IL-2Rγ); differences were limited to assay setup details such as the specific chip, immobilized ligand, pH for coupling, and regeneration conditions optimized for each subunit. e Domain architecture of VHH-hFc fusion constructs used for biochemical and cellular assays.

Article Snippet: The potency of bispecific and trispecific anti-IL-2R antibodies to induce IL-2 signaling was analyzed by determining the level of STAT5 phosphorylated by the HEK-Blue IL-2 recombinant cell line (Invivogen, #hkb-il2) in the presence of the antibodies.

Techniques: Selection, Clone Assay, Sequencing, Binding Assay, Recombinant, Injection, Derivative Assay, Construct

a Fc-fused IL-2 mutein (V91K) and formats of the trispecific 2:1 anti-CD25:anti-CD122/CD132 antibodies used in the study. Recombinant human IL-2 and the parental trispecific αβγVHH-48 were used as reference agonists. αVHH in blue, βVHH in green, γVHH in yellow. b – d Dose-dependent STAT5 activity of native IL-2, selected trispecific 2:1 anti-CD25:anti-CD122/CD132 antibodies and the Fc-fused IL-2 mutein (V91K) in human PBMC subsets. b Results expressed as percentage of pSTAT5 + cells. c Difference in area under the curve (AUC) between Treg and non-Treg cell populations. d Results expressed as pSTAT5 mean fluorescence intensity (MFI). Dose-response curves were generated from experimental data using a three-parameter logistic (3PL) fit. Data are from two donors and shown as mean of both data points. IL-2Rα (CD25) expression levels for the PBMC donors used in these assays are shown in Fig. and Supplementary Fig. . e Purified Treg cell expansion was assessed by measuring absolute cell counts by flow cytometry after 7 days of culture. Gating strategies for Fig. 5b–d are shown in Supplementary Fig. , and for Fig. 5e in Supplementary Fig. . Data are from three donors, mean ± s.e.m.

Journal: Nature Communications

Article Title: Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting

doi: 10.1038/s41467-026-75024-6

Figure Lengend Snippet: a Fc-fused IL-2 mutein (V91K) and formats of the trispecific 2:1 anti-CD25:anti-CD122/CD132 antibodies used in the study. Recombinant human IL-2 and the parental trispecific αβγVHH-48 were used as reference agonists. αVHH in blue, βVHH in green, γVHH in yellow. b – d Dose-dependent STAT5 activity of native IL-2, selected trispecific 2:1 anti-CD25:anti-CD122/CD132 antibodies and the Fc-fused IL-2 mutein (V91K) in human PBMC subsets. b Results expressed as percentage of pSTAT5 + cells. c Difference in area under the curve (AUC) between Treg and non-Treg cell populations. d Results expressed as pSTAT5 mean fluorescence intensity (MFI). Dose-response curves were generated from experimental data using a three-parameter logistic (3PL) fit. Data are from two donors and shown as mean of both data points. IL-2Rα (CD25) expression levels for the PBMC donors used in these assays are shown in Fig. and Supplementary Fig. . e Purified Treg cell expansion was assessed by measuring absolute cell counts by flow cytometry after 7 days of culture. Gating strategies for Fig. 5b–d are shown in Supplementary Fig. , and for Fig. 5e in Supplementary Fig. . Data are from three donors, mean ± s.e.m.

Article Snippet: The potency of bispecific and trispecific anti-IL-2R antibodies to induce IL-2 signaling was analyzed by determining the level of STAT5 phosphorylated by the HEK-Blue IL-2 recombinant cell line (Invivogen, #hkb-il2) in the presence of the antibodies.

Techniques: Recombinant, Activity Assay, Fluorescence, Generated, Expressing, Purification, Flow Cytometry

Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Article Title: RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators

doi: 10.1002/smll.201803284

Figure Lengend Snippet: Optimizing IS-LSNA NF-κB activity. A) Five ssRNA sequences (Table S1, Supporting Information) free and cationic lipid-transfected (LyoVec) were screened to identify their potency in activating TLR7/8 in Raw Blue cells (InvivoGen). ssRNA-DR gave the best activity both as free RNA and with a cationic transfection agent, which for concentrations greater than 100 × 10−9 M, was statistically significantly (p < 0.05) than any of the other tested ssRNA sequences (*). B) NF-κB activity of free RNA, cationic lipid-transfected RNA, and LSNA with either a PO or PS backbone was tested using Raw Blue cells (InvivoGen). A PS backbone gave significantly higher NF-κB activity. * and ** indicate p < 0.05 and 0.01. C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for their potency. A 5′-hydrophobic moiety gave the best NF-κB activity, suggesting that the 3′- end of the RNA is crucial for binding to TLR7/8. **** denotes p < 0.0001. D) LSNAs functionalized with 5′-cholesterol or 5′-tocopherol were tested in both Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for its NF-κB activity. A 5′-cholesterol gave higher activity than 5′-tocopherol, with p < 0.05 for mTLR7 at LSNA concentrations greater than 100 × 10−9 M (by RNA) and at all concentrations for hTLR8. E) LSNAs functionalized with 5′-cholesterol-modified RNA with and without 2 PEG spacer units (hexaethylene glycol), were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen). The use of PEG spacers did not improve hTLR8 binding, and were not used for future experiments. **** denotes p < 0.0001. F) IS-LSNAs increased the NF-κB activation of TLR 7/8 in engineered Hek-Blue cells compared to free RNA, cationic lipid-transfected RNA, or non-immunostimulatory LSNA (Ctl-LSNA). At above 100 × 10−9 M of IS-LSNA (by RNA), it is statistically significantly (p < 0.05) different than free or cationic-lipid transfected RNA in both mTLR7 and hTLR8 expressing Hek-Blue cells (*). G) IS-LSNAs likely activate TLR7/8 in endosomal compartments, as little NF-κB activation is observed in the presence of chloroquine, an endosomal maturation blocker. p ≤ 0.0001 between all constructs with and without chloroquine treatment. For all groups except for Ctl-LSNA activating hTLR8, p < 0.0001 between all samples with and without chloroquine. For all graphs in this figure, results are representative of at least three independent experiments; bars represent mean ± SD, with n = 3.

Article Snippet: C) RNA capped with either a 5′- or 3′-cholesterol was functionalized onto an LSNA; LSNAs were tested in Hek-Blue mTLR7 and hTLR8 cells (InvivoGen) for their potency.

Techniques: Activity Assay, Transfection, Binding Assay, Modification, Activation Assay, Expressing, Construct